within Pharmacolibrary.Drugs.ATC.R;

model R03DA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.0008166666666666667,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.00044,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013666666666666666,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Doxofylline is a xanthine derivative used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It exhibits bronchodilatory effects by inhibiting phosphodiesterase enzymes. Doxofylline is distinguished from other xanthines (like theophylline) by having fewer adverse effects and drug interactions. It is currently approved and used in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose of 400 mg.</p><h4>References</h4><ol><li><p>Bologna, E, et al., &amp; Biffignandi, P (1990). Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. <i>The Journal of international medical research</i> 18(4) 282–288. DOI:<a href=&quot;https://doi.org/10.1177/030006059001800404&quot;>10.1177/030006059001800404</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2227075/&quot;>https://pubmed.ncbi.nlm.nih.gov/2227075</a></p></li><li><p>Huang, HF, et al., &amp; Tang, X (2008). Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. <i>Drug development and industrial pharmacy</i> 34(7) 676–682. DOI:<a href=&quot;https://doi.org/10.1080/03639040701836552&quot;>10.1080/03639040701836552</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18608467/&quot;>https://pubmed.ncbi.nlm.nih.gov/18608467</a></p></li><li><p>Shukla, D, et al., &amp; Mishra, B (2012). Evaluation of in vivo behavior of controlled and pulsatile release pastilles using pharmacokinetic and γ-scintigraphic techniques. <i>Expert opinion on drug delivery</i> 9(11) 1333–1345. DOI:<a href=&quot;https://doi.org/10.1517/17425247.2012.716825&quot;>10.1517/17425247.2012.716825</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22924769/&quot;>https://pubmed.ncbi.nlm.nih.gov/22924769</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03DA11;
